ArticleHereditas2025
miR-671-5p as a diagnostic biomarker and therapeutic target in periodontitis via THBS1 regulation.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Coding RNAs in Oral Diseases: From Pathogenesis to Clinical Translation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly diagnosis and therapeutic targeting of periodontitis remain challenging. This study aimed to investigate the clinical relevance and mechanistic role of miR-671-5p in pathogenesis of periodontitis.
methodsClinical data and gingival crevicular fluid (GCF) samples were collected from 78 periodontitis patients and 79 healthy controls. miR-671-5p expression in GCF was quantified via quantitative reverse transcription polymerase chain reaction (qRT-PCR), and the diagnostic efficacy was evaluated by receiver operating characteristic (ROC) analysis. To model inflammation, lipopolysaccharide (LPS)-stimulated human periodontal ligament fibroblasts (hPDLFs) were employed. Subsequently, miR-671-5p mimics or inhibitors were transfected to assess effects on cell viability assessed by CCK-8, cellular migration measured via Transwell assays, and cytokine secretion analyzed using enzyme-linked immunosorbent assay (ELISA). THBS1 targeting by miR-671-5p was validated via dual-luciferase assays.
resultsmiR-671-5p expression was significantly reduced in GCF of periodontitis patients, and a strongly correlation was observed with clinical severity indices. ROC analysis revealed high diagnostic accuracy. Furthermore, miR-671-5p levels exhibited an inverse correlation with TNF-α, IL-6, and IL-1β. In LPS-treated hPDLFs, miR-671-5p was associated with a dose-dependent reduction in cell viability and migration, as well as an increase in the production of inflammatory cytokines. miR-671-5p was found to directly target THBS1 mRNA, inhibiting its expression. miR-671-5p overexpression reversed LPS-induced functional impairment and inflammation; these beneficial effects were partially counteracted by THBS1 upregulation.
conclusionsmiR-671-5p holds promise as a potential diagnostic biomarker and therapeutic target in periodontitis by regulating THBS1-mediated inflammatory responses and dysfunction of hPDLFs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.